

REMARKS

Claims 18-24 and 26-28 are pending. Support for the language in claim 21 is found on page 7, lines 25-34, page 9, lines 18-20, page 34, lines 19-20, and page 35, lines 1-2 of the specification. This amendment is present to clarify that the subject matter of the invention is a composition, rather than a method.

No new matter is added by this amendment.

Attached hereto is a "Version With Markings to Show Changes Made" (Appendix A) and a "Clean Copy of Pending Claims Without Markings" (Appendix B).

The Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for the Applicants

By Cathy A. Kodloff  
Cathy A. Kodloff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Phone: (215) 540-9210  
Fax: (215) 540-5818

**Appendix A****Version with Markings to Show Changes Made****In the claims:**

Claim 21 has been amended as follows:

21. (Thrice Amended) A composition comprising a recombinant adeno-associated virus (AAV) suspended in a biologically compatible carrier, wherein said recombinant AAV comprises (a) 5' AAV inverted terminal repeats (ITRs), (b) nucleic acid sequences encoding human apolipoprotein E (ApoE), and (c) 3' AAV ITRs, and wherein the level of contaminating adenoviral helper virus is no greater than that obtained by subjecting said recombinant AAV to four rounds of cesium chloride gradient centrifugation, ~~and wherein the ApoE is expressed in the absence of a cytotoxic immune response directed against recombinant AAV-transduced cells expressing the ApoE.~~